News
Apogee’s pipeline in a product drug zumilokibart achieved significant disease clearance in a mid-stage atopic dermatitis trial, but investors were miffed by a royalty financing deal with Blackstone.
FEATURED STORIES
From Eli Lilly’s David Ricks to Pfizer’s Albert Bourla, the top five highest paid CEOs made a combined $157.8 million in 2025.
Partners Summit Therapeutics and Akeso are expected to steal the show at the American Society of Clinical Oncology’s annual conference with data from their potential Keytruda rival, alongside Revolution Medicine’s groundbreaking pancreatic cancer candidate and other assets that could reshape patient care.
The tragic tale of TIGIT is well known. However, RIPK1, myc, STING and alpha-synuclein have also left a trail of failed clinical trials, canceled partnerships and sunk investments in their wake.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
The Department of Health and Human Services is spinning its wheels, unable to establish steady leadership at three major divisions—the CDC and the FDA’s two primary review units.
THE LATEST
Umoja CEO Andy Scharenberg spoke with BioSpace about the company’s unique tri-platform approach to immunotherapy which aims to attack and destroy hematologic and solid organ-based tumors.
Vilya will use its funds for cutting-edge computational techniques to develop innovative drugs for difficult-to-treat diseases.
Alnylam Pharmaceuticals reported positive Phase II results for cemdisiran, an RNA interference (RNAi) drug developed to treat IgA nephropathy.
The Artemis I space mission hopes to provide researchers with a better understanding of the high levels of radiation on the body for cancer treatment and other applications.
AstraZeneca reported a pre-specified pooled analysis from its Phase III trial of the diabetes drug Farxiga in patients with heart failure.
Phase III data shows the potential of Bayer’s Kerendia to reduce the risk of all-cause and cardiovascular mortality in type 2 diabetes patients with chronic kidney disease.
Factor XIa inhibitors developed by Bayer and the duo of BMS and Janssen Pharmaceuticals missed Phase II endpoints in data presented at ESC.
89bio presented positive data for pegozafermin in SHTG, Tonix enrolled its first patient with Long COVID for TNX-102, Belite enrolled patients with STGD1 and more clinical trial news.
Despite being the largest minority group in the United States, the contributions of disabled people are remarkedly underreported in the life sciences industry.
The BioForest region is growing up. With a focus on cell and gene therapy, a wealth of talent and proximity to high tech, it is quickly becoming one of biotech’s most exciting hotbeds.